Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer
Study Information
Alliance Study ID: CALGB-49806
NCT Study ID (ClinicalTrials.gov): NCT00004893
Alliance Committee: Breast Cancer
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Daniel F. Hayes, MD
Status: COMPLETED
Study Description
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person’s white blood cells to kill breast cancer cells.
PURPOSE: Randomized phase II trial to study the effectiveness of interleukin-12 in treating patients who have metastatic or recurrent breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information